According to the National Bureau of Statistics, in 2012, the revenue of enterprises above designated size in China's medical device industry reached 156.5 billion, with an average annual compound growth rate of over 20%. With the aging population and significant improvement in health care awareness, the average growth rate of the medical device industry will be higher than that of the pharmaceutical industry in the future. PE funds have also been holding onto the 'no love' policy; Taking medication; Practice hard&# quo; Instruments; Attitude.
And the national 12th Five Year Plan has increased the development of medical machinery. The country has stated that it will focus on supporting 10 to 15 large medical device enterprise groups, supporting 40 to 50 innovative high-tech enterprises, establishing 8 to 10 medical device technology industry bases, and 10 national level innovative medical device product demonstration and application bases.
At present, the size of China's medical device market accounts for 14% of the total pharmaceutical market, which is far from the global level of 42%. This also shows the investment community that there is huge exploration space in this field. Chen Penghui, the Managing Director of Everbright Holdings, believes that the activity of the medical device M&A market has also given more investors opportunities before the IPO.
Industry insiders have stated that there are relatively few high-tech talents in the pharmaceutical industry, and there are relatively large opportunities for high-end chemical generic drugs and children's medication. However, pharmaceutical companies have a large initial investment, a long product approval cycle, and high requirements for technology and talent have set an invisible high threshold for them. Moreover, investment in small molecule chemical drugs should not only be cautious, but also bear the risk of low success probability. Therefore, the company is more optimistic about investing in medical devices and medical services, and has less attention to traditional biopharmaceuticals.
In addition, the new GMP plan has also played a driving role in the development of the pharmaceutical machinery industry. The new GMP has high requirements for sterile preparation enterprises, requiring all to pass by the end of 2013. Therefore, pharmaceutical companies will develop towards higher requirements and will inevitably pursue high-end medical machinery. (Extracted from Kexun Network)
